Lifecore Biomedical Earnings & Forecasts

Lifecore Biomedical (LFCR) earnings history, EPS estimates, revenue forecasts and company guidance.

Earnings Per Share (Non-GAAP)

분기별 실적 서프라이즈 금액

회계 분기	보고된 날짜	실제 EPS	예상 EPS	놀라다 %
Q2	Aug 5, 2026	$-0.19	$-0.21	9.52 %
Q1	May 6, 2026	$-0.43	$-0.28	-53.6 %
Q1	Nov 6, 2025	$-0.29	$-0.30	3.33 %
Q4	Aug 7, 2025	$-0.06	$-0.09	33.3 %

Quarterly Revenue (Billions)

분기별 수익 깜짝 금액

회계 분기	보고된 날짜	실제 수익	예상 수익	놀라다 %
Q2	Aug 5, 2026	$34.20M	$32.05M	6.71 %
Q1	May 6, 2026	$23.19M	$26.30M	-11.8 %
Q1	Nov 6, 2025	$31.11M	$26.56M	17.2 %
Q4	Aug 7, 2025	$36.44M	$35.52M	2.61 %

Lifecore Biomedical Guidance

Lifecore Biomedical (LFCR)는 8월 5, 2026에 fiscal year 2026에 대한 가이던스를 마지막으로 발표했습니다. 회사는 해당 기간의 매출을 $120M - $125M 범위로 예상했습니다.

이전 가이던스와 비교하여 Lifecore Biomedical는 매출 전망치를 이전 범위인 유지됨에서 $120M - $125M로 상향 조정했습니다.

Lifecore Biomedical은 7과 4월 1, 2024 사이에 8월 5, 2026개의 지침 업데이트를 발표했습니다. During this period, the company lowered its outlook 1 time, signaling management's revised expectations.

Recent Earnings Results

Metric	Q2 '26	Q1 '26	Q4 '25	Q1 '26
Earnings Per Share (Non-GAAP)
Estimate	$-0.21	$-0.28	—	$-0.30
Actual	$-0.19	$-0.43	$-0.16	$-0.29
Surprise	+9.52%	-53.6%	—	+3.33%
Revenue
Estimate	$32.1M	$26.3M	—	$26.6M
Actual	$34.2M	$23.2M	$35.7M	$31.1M
Surprise	+6.71%	-11.8%	—	+17.2%

Analyst Estimates — Forward PeriodsSource: Wall Street consensus

Metric	Q3 '26E	Q4 '26E	Q1 '27E	Q2 '27E
Earnings Per Share (Non-GAAP)
Consensus	$-0.30	$-0.10	$-0.30	$-0.22
Revenue
Consensus	$25.6M	$38.4M	—	—

More with Benzinga EdgeGet Access

Earnings & Guidance News

PRO
Lifecore Biomedical Q2 EPS $(0.19) Beats $(0.22) Estimate, Sales $34.200M Beat $32.016M Estimate

Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.22) by 13.64 percent. This is a 24 percent increase over losses of $(0.25) per share from

Benzinga Newsdesk

PRO
Lifecore Biomedical Affirms FY2026 Sales Guidance of $120.000M-$125.000M vs $122.176M Est

Lifecore Biomedical (NASDAQ:LFCR) affirms FY2026 sales outlook from $120.000 million-$125.000 million to $120.000 million-$125.000 million vs $122.176 million estimate.

Benzinga Newsdesk

Earnings Scheduled For May 6, 2026

Benzinga Insights

PRO
Lifecore Biomedical Affirms FY2026 Sales Guidance of $120.000M-$125.000M vs $122.430M Est

Lifecore Biomedical (NASDAQ:LFCR) affirms FY2026 sales outlook from $120.000 million-$125.000 million to $120.000 million-$125.000 million vs $122.430 million estimate.

Benzinga Newsdesk

PRO
Lifecore Biomedical Q1 EPS $(0.43) Misses $(0.24) Estimate, Sales $23.193M Miss $26.501M Estimate

Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.24) by 79.17 percent. This is a 18.87 percent increase over losses of $(0.53) per share

Benzinga Newsdesk

PRO
CORRECTION: Lifecore Biomedical Q4 EPS $(0.16) Up From $(0.20) YoY, Sales $35.747M Down From $37.886M YoY

Lifecore Biomedical (NASDAQ:LFCR) reported quarterly losses of $(0.16) per share. This is a 20 percent increase over losses of $(0.20) per share from the same period last year. The company reported $35.747 million in

Benzinga Newsdesk

Lifecore Biomedical Inc